No. | | Times Cited: |
|---|
1. | Garcia-Closas M, Malats N, Silverman D, et al.
NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses.
LANCET 366 (9486): 649-659 AUG 20 2005 | 83 |
2. | Sylvester RJ, van der Meijden APM
Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: A combined analysis of 2596 patients from seven EORTC trials. EUROPEAN UROLOGY 49 (3): 466-477 MAR 2006 | 79 |
3. | von der Maase H, Sengelov L, Roberts JT, et al.
Long-term-survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer.
JOURNAL OF CLINICAL ONCOLOGY 23 (21): 4602-4608 JUL 20 2005 | 74 |
4.. | van Rhijn BWG, van der Poel, van der Kwast TH Urine markers for bladder cancer surveillance: A systematic review
EUROPEAN UROLOGY 47 (6): 736-748 Jun 2005 | 64 |
5. | Grossman HB, Messing E, Soloway M, et al.
Detection of bladder cancer using a point-of-care proteomic assay.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION 293 (7): 810-816 FEB 16 2005 | 63 |
6. | Kirkali Z, Chan T, Manoharan M, et al. Bladder cancer: Epidemiology, staging and grading, and diagnosis UROLOGY 66 (6A): 4-34 Suppl. S DEC 2005 | 47 |
7. | Nogawa M, Yuasa T, Kimura S, et al.
Intravesical administration of small interfering RNA targeting PLK-1 successfully prevents the growth of bladder cancer. JOURNAL OF CLINICAL INVESTIGATION 115 (4): 978-985 APRIL 2005 | 44 |
8. | Grossman HB, Soloway M, Messing E, et al.
Surveillance for recurrent bladder cancer using a point-of-care proteomic assay
Source: JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION Volume: 295 Issue: 3 Pages: 299-305 Published: JAN 18 2006 | 43 |
9. | Wu XF, Gu J, Grossman HB, et al. Bladder cancer predisposition: A multigenic approach to DNA-repair and cell-cycle-control genes AMERICAN JOURNAL OF HUMAN GENETICS 78 (3): 464-479 MAR 2006 | 41 |
10. | Iliopoulos D, Guler G, Han SY, et al. Fragile genes as biomarkers: epigenetic control of WWOX and FHIT in lung, breast and bladder cancer ONCOGENE 24 (9): 1625-1633 FEB 24 2005 | 41 |
